Bausch Health Companies Inc. (BHC)

On our fundamental equity desk, the Q2 print was an absolute eye-opener. BHC delivered non-GAAP EPS of $1.26, beating consensus by a wide margin, backed by 13% revenue growth to $2.85 billion. Salix, Solta, and a 26% jump in Xifaxan revenues proved that core operations remain highly productive. However, the market reaction has been bifurcated due to the massive $15 billion debt overhang. While some see a deeply undervalued asset with a GoodMoat value sitting way higher, the reality of speculative credit ratings and an $800 million H1 interest expense keeps our long-term conviction tempered.

From a risk management standpoint, the debt profile is a ticking clock that overshadows operational successes. Even though Bausch Health (excluding Bausch + Lomb) generated an impressive Adjusted EBITDA margin of 59.3% and strong cash flows, the structural liabilities cannot be ignored. Looking ahead into the second half of the year, management highlighted visible headwinds including inventory accruals, loss of exclusivity, and mounting pressure from Medicaid and 340B erosion. We are advising clients to watch out for liquidity squeezes if execution stumbles.

As a gastrointestinal therapeutic specialist tracking Rx volumes, the strength in Xifaxan and the broader Salix portfolio is entirely real in clinical practice. Physicians continue to rely heavily on these therapies for hepatic encephalopathy and IBS-D, creating a durable moat that generated thirteen consecutive quarters of top-line growth for the standalone segment. Yet, questions are always raised in expert network calls regarding how long pricing power can offset regulatory and rebate pressures, particularly with Medicaid/340B erosion looming over margins.

As a hedge fund portfolio manager, trading BHC requires a sophisticated understanding of capital structure distress versus operational turnaround. The stock surged roughly 40% post-Q2 and management raised guidance across all metrics for FY2026, which caught shorts off guard and drove heavy volume into oversold territory. Despite the cheap P/E multiples and robust organic growth, corporate governance questions—such as Michael Goettler resigning from the Board of Directors—introduce subtle headline risks that make sizing long positions tricky.

As a specialty pharma equity analyst, the most striking takeaway from the Q2 transcripts was the dramatic 530 basis point expansion in Adjusted EBITDA margin for the non-Bausch + Lomb business, hitting 59.3%. Management's cost-containment and productivity initiatives executed since the start of the year are yielding tangible results. However, institutional sentiment remains fragile; equity investors are constantly weighing this operational leverage against the sheer weight of the company's fixed financial obligations.